Auction Closed
Auction Details
Users can contribute funds anytime during the auction, up to a maximum total contribution cap. If the minimum raise isn’t met, the auction is voided, and all funds are refundable. At the end, tokens are distributed pro-rata based on contributions.
02/22/2025
9:14 PM
02/22/2025
9:14 PM
$1 Trillion
Dollar Rare Disease Market
1 in 10
people on Earth suffers from a rare disease
95%
of the 10,000 rare diseases have no treatment option today
The average likelihood of Clinical trial success from Phase 1 to approval is twice as high for rare diseases (17%) versus all diseases (8%).
Additional documentation
📄 Download litepaperThere are 10,000 rare diseases with an average market size of $1500M. Traditional pharma corporations are such large and complex institutions that they need a $1B+ TAMs to even begin exploring a disease. The same is true for a traditional VC backed b...
Identification of a candidate yeast avatar
First we confirm that yeast have an ancestral version of a human disease gene. Because yeast have been poked and prodded in the lab for decades, many of the rare disease genes we seek to model in yeast have already been studied.
Screening yeast avatar against drug repurposing library
We have had great success with a 8,400-compound drug repurposing library called TargetMol, which offers a wide selection of clinically actionable compounds including generic drugs and over-the-counter supplements/nutraceuticals.
Creation of yeast-patient avatar with gene engineering
In almost all cases we can leverage already existing yeast avatars that were generated and characterized by academic labs, sometimes as long as two decades ago. When necessary, we can dial in a specific mutation at practically any location in the yeast genome using gene engineering techniques that predate CRISPR-Cas9.
100,000,000
Total Supply
＠endrarediseases on 𝕏
Telegram community
Curetopia captures value by leveraging the power of a decentralized and mission-driven community to tackle the $1 trillion rare disease market, which has long been overlooked by traditional pharmaceutical companies and VC-backed biotech startups. Usi...
Perlara Substack
1-to-N medicine
Perlara Substack
The Anti-Portfolio of Pharma
Perlara Substack
